Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Plasma NfL and GFAP for predicting VCI and related brain changes in community and clinical cohorts
Raghavan, Sheelakumari , Graff‐Radford, Jonathan , Hofrenning, Ekaterina I. , Fought, Angela J. , Kamykowski, Michael G. , Windham, B. Gwen , Lowe, Val J. , Jack, Clifford R. , Petersen, Ronald , Hofrenning, Ekaterina, Jack, Clifford R , Reid, Robert I. , Algeciras‐Schimnich, Alicia , Knopman, David S. , Vemuri, Prashanthi

Alzheimer's & Dementia | June 26, 2025 | Volume: 21 | Issue: 6 | Pages: No page available

10.1002/alz.70381 | PMID 40566826 Get It

AbstractINTRODUCTIONWe investigated the usefulness of plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) for capturing vascular cognitive impairment (VCI) in the context of amyloidosis.METHODSUsing two independent cohorts (n = 1810), we assessed the relationship of plasma NfL and GFAP with (1) vascular brain indices; (2) diagnostic states using the following definitions: vascular versus not (white matter hyperintensity/total intracranial volume ≥ 1.3%), and cognitively impaired (CI) versus cognitively unimpaired (CU) using Clinical Dementia Rating ([CDR] scale ≥ 0.5); and (3) their upstream predictors using structural equation models (SEMs).RESULTSPlasma NfL and GFAP were associated with vascular brain damage and differed across states (VCI > vascular CU > non‐vascular CI > non‐vascular CU). In a population‐based sample, these biomarkers distinguished vascular CU and VCI from non‐vascular CU groups with greater separation in amyloid negative participants. Pathway analyses showed NfL was primarily influenced by systemic/brain vascular health, whereas amyloid contributed to GFAP variability.DISCUSSIONPlasma biomarkers, particularly NfL, capture vascular brain changes and show promise for VCI identification.Highlights Plasma NfL and glial fibrillary acidic protein (GFAP) were associated with vascular brain indices. Plasma biomarkers differed across diagnostic states (VCI > vascular CU > non‐vascular CI > non‐vascular CU). Plasma markers discriminated vascular from non‐vascular states with greater separation in Aβ− participants. NfL was linked to vascular health, while amyloid influenced GFAP variability in the population‐based sample. Future longitudinal frameworks should consider systemic inflammation markers along with these plasma markers to better understand VCID‐related brain changes and cognitive decline.
Ultrafast Measurement of Circulating Ceramides in Human Cohorts
Tham, Wai Kin , Teo, Guo Shou, Vasile, Vlad C. , Meeusen, Jeffrey W. , Torta, Federico , Chang, Jing Kai , Teo, Guoshou , Ekroos, Kim , Futerman, Anthony H. , Kuan, Win Sen , Choi, Hyungwon , Wenk, Markus Rene

Analytical Chemistry | June 25, 2025 | Volume: 97 | Issue: 26 | Pages: 13789-13798

10.1021/acs.analchem.5c00058 | PMID 40561519 Get It

Asthma and inflammation transcriptionally up‐regulate the aryl hydrocarbon receptor in airway smooth muscle via p38/JNK‐AP1 signalling
Balraj, Premanand , Britt, Rodney D. , Sathish, Venkatachalem , Sathish, Venkatachalem , Reza, Mohammad Irshad , Thompson, Michael A. , Prakash, Y. S. , Pabelick, Christina M.

British Journal of Pharmacology | June 25, 2025 | Volume: 182 | Issue: 21 | Pages: 5269-5285

10.1111/bph.70120 | PMID 40562410 Get It

Background and PurposeThe aryl hydrocarbon receptor (AhR) is a ligand‐activated transcription factor that maintains cellular homeostasis. AhR in airway fibroblasts, epithelial and immune cells inhibit inflammatory responses. Nevertheless, its expression and role in airway smooth muscle (ASM), an airway structural cell indispensable in asthma pathophysiology, are obscure. This study uncovers AhR expression, underlying mechanisms, and activity in ASM during inflammation and asthma.Experimental ApproachCultured primary human nonasthmatic and asthmatic ASM cells were treated with TNFα/IL‐13, with/without pharmacological inhibitors targeting PI3K, p38MAPK, JNK, NFkB, and AP1. AhR expression was analysed using RNA‐sequencing, confocal microscopy, qPCR, and immunoblotting. AP1 specific role was confirmed using c‐JUN (AP1) siRNA and ChIP‐qPCR. AhR activity was determined by Nano luciferase in AhR agonist‐treated cells.Key ResultsWe found ubiquitous expression of AhR in ASM with up‐regulation in asthmatic ASM. TNFα increased AhR expression, whereas IL‐13 did not. Furthermore, p38 and JNK inhibition significantly reduced AhR expression with TNFα exposure, whereas PI3K inhibition had no effect. AP1 inhibition and c‐JUN knockdown significantly down‐regulated AhR expression, whereas NFkB inhibition showed no effect. TNFα promoted c‐JUN binding to AhR promoter and increased AhR mRNA expression. Additionally, AhR agonists significantly increased the xenobiotic response element (XRE) activity, CYP1B1, and AhR nuclear expression. TNFα exposure reduced XRE activity and AhR nuclear expression.Conclusion and ImplicationsOur findings suggest inflammation and asthma transcriptionally up‐regulates AhR through the p38/JNK‐AP1 pathway in ASM, identifying a potential therapeutic target for modulating AhR and its downstream effects in asthma.
Evaluation of a Photovoice Exhibit About Immigrant Health Priorities in Southeast Minnesota
Lohr, Abby M. , Ahmed, Yahye, Dirie, Hana, Molina, Luz, Capetillo, Graciela Porraz, Iteghete, Sheila, Smith, Kaitlyn, Jefferson, Laken, Griffin, Joan M. , Wieland, Mark L , Sia, Irene G , Griffin, Joan M , Wieland, Mark L. , Sia, Irene G.

American Journal of Public Health | June 25, 2025 | Volume: 115 | Issue: S2 | Pages: S120-S125

10.2105/ajph.2025.308098 | PMID 40561403 Get It

Rochester Healthy Community Partnership, a 20-year community based participatory research partnership, used photovoice to learn about Hispanic/Latino and Somali immigrants’ health concerns. Participants photographed their health-related priorities, reflected, developed policy recommendations, and shared photographs at a public event and rotating exhibit in 2024. More than 100 people attended the event (19 decision makers, 64 members of the public, 11 immigrant leader participants, 11 research staff). All decision-maker and public survey respondents reported learning something new about the priorities of Hispanic/Latino and Somali immigrants. ( Am J Public Health. 2025;115(S2):S120–S125. https://doi.org/10.2105/AJPH.2025.308098 )
C-Type Natriuretic Peptide: Protecting the Aorta
Sangaralingham, S. Jeson , Burnett, John C. , Sangaralingham, S. Jeson

Arteriosclerosis, Thrombosis, and Vascular Biology | June 25, 2025 | Volume: 45 | Issue: 7 | Pages: 1064-1066

10.1161/atvbaha.125.322802 | PMID 40560989 Get It

Efficacy and safety of thrombolysis for pediatric venous thromboembolism: a systematic review and meta-analysis
Kawtharany, Hassan , Azzam, Muayad , Alkhader, Aseel, Betensky, Marisol , Hamarsha, Qais, Mansour, Razan , Tabak, Carine , Bhat, Rukhmi , Biss, Tina , Brandão, Leonardo R. , Chan, Anthony K.C. , Faustino, E. Vincent S. , Jaffray, Julie , Jones, Sophie , Kerlin, Bryce A. , Pelland‐Marcotte, Marie‐Claude , Raulji, Chittalsinh M , Sartain, Sarah E. , Ommen, C. Heleen van , Wiernikowski, John , Williams, Suzan , Wilson, Hope P. , Woods, Gary , Zia, Ayesha , Abou Zeid, Hadi K, Brandão, Leonardo R , Chan, Anthony K C , Jaffray, Julie , Jones, Sophie , Kerlin, Bryce A , Kucine, Nicole , Male, Christoph , Pelland-Marcotte, Marie-Claude , Raffini, Leslie , Raulji, Chittalsinh M , Tarango, Cristina , van Ommen, C Heleen , Velez, Maria C , Vesely, Sara K , Zia, Ayesha , Monagle, Paul , Mustafa, Reem A , Kawtharany, Hassan , Hamarsha, Qais , Zeid, Hadi Khaled Abou , Patel, Payal Mukesh , Baghdadi, Sarah L., Bercovitz, Rachel S. , Branchford, Brian R. , Kumar, Riten , Takemoto, Clifford M.

Blood Advances | June 25, 2025 | Volume: 9 | Issue: 21 | Pages: 5512-5527

10.1182/bloodadvances.2025017058 | PMID 40561511 Get It

Abstract We conducted this systematic review to evaluate outcomes of thrombolysis followed by anticoagulation vs anticoagulation alone in pediatric patients with venous thromboembolism (VTE). This systematic review addresses mortality, VTE resolution, recurrence, bleeding, and organ-specific outcomes in 5 PICO (population, intervention, comparison, outcomes) questions on thrombolysis across pulmonary embolism (PE), extremity deep vein thrombosis (DVT), right atrial thrombosis (RAT), cerebral sinus venous thrombosis (CSVT), and renal vein thrombosis (RVT). Meta-analysis reported risk ratios or differences (95% confidence intervals [CIs]), and absolute effects per 1000 patients. Certainty of evidence was assessed using GRADE (Grading of recommendation, assessment, Development, and Evaluation) guidelines. Thirteen nonrandomized studies were included and no randomized clinical trials addressed these questions. Thrombolysis might be associated with a higher risk of major bleeding, clinically relevant nonmajor bleeding, or unspecified bleeding with risk differences of 0.09 (95% CI, −0.06 to 0.23), 0.06 (95% CI, −0.11 to 0.22), and 0.09 (95% CI, −0.04 to 0.23), respectively. In PE with hemodynamic compromise, thrombolysis might be associated with a lower risk of mortality but conclusions on PE progression were uncertain in submassive PE. In DVT, thrombolysis may have little to no effect on mortality or thrombus resolution but might be associated with lower risk of postthrombotic syndrome. In RAT, thrombolysis might have little to no effect on thrombus resolution but a higher risk of major bleeding and mortality. For CSVT and RVT, the evidence was very limited. These findings were based on very-low-certainty evidence because of confounding and imprecision from small sample sizes. This systematic review highlights key challenges in developing recommendations for thrombolysis in children with VTE.
Discussion: Remote Incisions as an Alternative to Mastectomy Scars for Breast Tissue Expander–to-Implant Exchange: A Propensity Score–Matched Analysis
Harless, Christin A., Nguyen, Minh-Doan T., Nguyen, Minh-Doan T.

Plastic & Reconstructive Surgery | June 25, 2025 | Volume: 156 | Issue: 1 | Pages: 16-17

10.1097/prs.0000000000012024 | PMID 40561440 Get It

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study
Zeiser, Robert , Russo, Domenico , Ram, Ron , Hashmi, Shahrukh K. , Chakraverty, Ronjon , Middeke, Jan Moritz , Musso, Maurizio , Uzay, Ant , Langmuir, Peter, Burock, K., Gowda, Maanasa, Stefanelli, Tommaso , Lee, Stephanie J. , Hamad, Nada , Lee, Stephanie J , Teshima, Takanori , Locatelli, Franco , Giebel, Sebastian , Hamad, Nada

Journal of Clinical Oncology | June 25, 2025 | Volume: 43 | Issue: 23 | Pages: 2566-2571

10.1200/jco-24-02477 | PMID 40561385 Get It

In REACH3 (ClinicalTrials.gov identifier: NCT03112603 ), ruxolitinib was investigated versus best available therapy (BAT) for 3 years in patients with steroid-refractory/dependent chronic graft-versus-host-disease (SR/D-cGVHD). Patients received ruxolitinib (10 mg twice daily) or BAT for 24 weeks; thereafter (weeks 24-156), patients continued randomized treatment, entered long-term survival follow-up, or crossed over from BAT to ruxolitinib. In 329 randomly assigned patients (ruxolitinib: 165; BAT: 164), the median failure-free survival (FFS) was 38.4 months for ruxolitinib versus 5.7 months for BAT (hazard ratio, 0.36 [95% CI, 0.27 to 0.49]). Median duration of response (DOR) was not reached for ruxolitinib versus 6.4 months for BAT. Ruxolitinib-treated patients had a higher probability of FFS (ruxolitinib: 56.5%; BAT: 18.2%) and maintaining a response (ruxolitinib: 59.6%; BAT: 26.7%) at 36 months. Median overall survival was not reached. Nonrelapse mortality and malignancy relapse/recurrence events were low. In 70 patients who crossed over to ruxolitinib, the overall response rate (50.0%) at week 24 and best overall response (81.4%) during the crossover period were consistent with the primary analysis of randomly assigned patients. No new safety signals were observed. Ruxolitinib provided longer FFS and DOR than BAT, demonstrating sustained efficacy and manageable safety over 3 years of follow-up in patients with SR/D-cGVHD.
Differences in Orthopaedic Surgeon Merit-based Incentive Payment System (MIPS) Performance, Demographics, and Patient Populations Based on Patient Social Risk
Holle, Alejandro M. , Lin, Eugenia , Gill, Vikram S. , Haglin, Jack M. , Clarke, Henry D. , Holle, Alejandro

Journal of Bone and Joint Surgery | June 25, 2025 | Volume: 107 | Issue: 15 | Pages: 1726-1735

10.2106/jbjs.24.01419 | PMID 40560965 Get It

Background: The Centers for Medicare & Medicaid Services (CMS) Merit-based Incentive Payment System (MIPS) has undergone numerous changes to promote care for patients at high social risk. However, the effect of these changes on surgeon MIPS performance and caseload selection remains unclear. Thus, the purpose of this study was to evaluate how orthopaedic surgeon MIPS scores, demographics, practice characteristics, and patient populations varied on the basis of patient social risk in 2017 compared with 2021. Methods: CMS data were utilized to examine U.S. orthopaedic surgeons. Surgeons were placed into social-risk quintiles on the basis of the proportion of their patients who were dually eligible for Medicare and Medicaid, with the highest quintile representing the highest social risk. Demographics, practice location characteristics, patient data, and MIPS performance were assessed for the years 2017 and 2021. Differences between social-risk quintiles were assessed utilizing chi-square, Student t, and Wilcoxon signed-rank tests and multivariable logistic regression. Results: In 2017, surgeons with caseloads at the highest, compared with the lowest, social risk had lower MIPS performance scores (mean [and standard deviation], 66.0 ± 37.6 versus 70.1 ± 33.5; p < 0.001). However, in 2021, orthopaedic surgeons with caseloads at the highest, compared with the lowest, social risk had significantly higher MIPS performance scores (mean, 88.7 ± 16.9 versus 81.5 ± 18.3; p < 0.001). In terms of demographics, in 2021, orthopaedic surgeons with caseloads at the highest, compared with the lowest, social risk were more often women (9.2% versus 3.6%; p < 0.001), more often had a DO degree (11.2% versus 6.6%; p < 0.001), more recently graduated from medical school (mean, 23.0 ± 12.9 versus 25.7 ± 10.9 years; p < 0.001), and worked in areas with higher Distressed Communities Index (DCI) distress scores (mean, 56.9 ± 27.3 versus 35.1 ± 25.2; p < 0.001). Similar findings were present in 2017. Conclusions: The addition of the Complex Patient Bonus to the MIPS in 2020 may have reduced performance inequities in MIPS scoring for surgeons with caseloads at high social risk. However, the demographics and practice patterns of the orthopaedic surgeons caring for populations at the highest social risk remained consistent between years. Level of Evidence: Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence.